Capecitabine for locally advanced and metastatic colorectal cancer: A review

Table 2 Non-comparative phase II trials on Capecitabine with either Oxaliplatin or Irinotecan combination in patients with metastatic colorectal cancer

Author	Patients	Drugs used	Regimen	RR (%)	mTTP (mo)	MS (mo)
Cassidy et al[16]	96	Capecitabine	2000 mg/m2 per day (days 1-14)	55	7.7	19.5
		Oxaliplatin	130 mg/m2 day 1
Zeuli et al[17]	43	Capecitabine	2500 mg/m2 per day (days 1-14)	44	-	20
		Oxaliplatin	120 mg/m2 day 1
Borner et al[18]	43	Capecitabine	2500 mg/m2 per day (days 1-14)	49	5.9	17.1
		Oxaliplatin	130 mg/m2 day 1
Shields et al[19]	35	Capecitabine	1500 mg/m2 per day (days 1-14)	37.1	-	NR
		Oxaliplatin	30 mg/m2 day 1
Bajetta et al[20]	68	Capecitabine	2500 mg/m2 per day (days 2-15)	47	8.3	-
		Irinotecan	300 mg/m2 day 1
Bajetta et al[20]	66	Capecitabine	2500 mg/m2per day (days 2-15)	44	7.6	-
		Irinotecan	150 mg/m2 days 1and 8
Patt et al[21]	52	Capecitabine	2000 mg/m2 per day (days 2-15)	46	7.1	15.6
		Irinotecan	250 mg/m2 day 1
Cartwright et al[22]	49	Capecitabine	2000 mg/m2 per day (days 2-15)	45	5.7	13.4
		Irinotecan	240 mg/m2 day 1
Kim et al[23	43	Capecitabine	2000 mg/m2 per day (days 2-15)
		Irinotecan	100 mg/m2 days 1and 8	46.6	NR	NR
Rosati et al[24]	46	Capecitabine	1000 mg/m2 per day twice daily on days 1-14 every 3 wk	38	8	19.3
		Oxaliplatin	oxaliplatin 65 mg/m2 iv days 1 and 8
Garcia-Alfonso et al[25]	53	Capecitabine	1000 mg/m2/d twice daily on days 2-8 every 2 wk	32	9	19.2
		Irinotecan	irinotecan 175 mg/m2 on day 1

RR: Response rate; mTTP: Median time to progression; MS: Median survival; NR: Not recorded. All capecitabine doses were divided equally and dosed twice daily. Regimens were administered every 3 wk.